Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totaling 9,742 shares, a drop of 55.2% from the August 15th total of 21,732 shares. Based on an average daily volume of 41,401 shares, the short-interest ratio is currently 0.2 days.
Ono Pharmaceutical Trading Down 1.4%
OPHLY traded down $0.07 during trading on Wednesday, hitting $4.93. The company’s stock had a trading volume of 24,239 shares, compared to its average volume of 32,187. The firm’s 50 day moving average price is $5.01 and its two-hundred day moving average price is $4.99. Ono Pharmaceutical has a 12 month low of $3.71 and a 12 month high of $5.75.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
Further Reading
- Five stocks we like better than Ono Pharmaceutical
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
